AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

In a phase II trial, 16 breast cancer survivors who completed eight weeks of oxaloacetate supplementation reported improved cognitive symptoms and less fatigue. The findings are preliminary: the study was small and did not include a comparison group, so larger trials are needed to determine whether the supplement caused the changes and whether they hold up over time.

A small phase II clinical trial led by researchers at UCLA Health found that breast cancer survivors who took the supplement oxaloacetate for eight weeks reported less cognitive difficulty and fatigue. Of the 18 women enrolled, 16 completed the study; the researchers say the results are promising but preliminary and do not establish that the supplement caused the improvements.

Before you orderOffer from Amazon

Get workout gear delivered free with Prime

  • Fast, free delivery on millions of items
  • Prime Video, Amazon Music and more included
  • Member-only deals all year
Start your free Prime trial Free trial for eligible customers · Cancel anytime
As an affiliate, we earn on qualifying purchases.

Participants were women diagnosed with early-stage breast cancer one to five years before the trial, all of whom reported substantial cognitive difficulties when they joined. They took 500 milligrams twice daily for eight weeks. Researchers tracked symptoms with participant questionnaires and standardized tests covering areas such as memory, attention, processing speed and executive function.

Among those who completed the trial, every participant reported improvement in cognitive symptoms. The group’s average score on the study’s main measure of perceived cognitive impairment rose from 29.1 before treatment to 55.5 after eight weeks, a level the report describes as within the normal rather than impaired range. Improvements were also reported after four weeks, and participants reported less fatigue and better physical functioning. Tests showed improvement in processing speed and executive function.

The supplement was generally well tolerated during the study, according to the report. Digestive complaints, including indigestion, were the most frequently reported side effects. Two of the 18 participants did not complete the full eight weeks. The supplied report does not give further details about why they left or provide a full breakdown of adverse events.

At a glance
reportWhen: Study results published in JCO Oncology…
The developmentA small UCLA-led phase II trial found reported and test-measured cognitive improvements among breast cancer survivors who took oxaloacetate for eight weeks.

Potential Relief for Lasting Cognitive Symptoms

Memory problems, difficulty concentrating and mental exhaustion can affect daily life well after cancer treatment ends. The study report estimates that about 15% to 25% of breast cancer survivors experience ongoing problems with memory, concentration or other thinking abilities. There are few established treatments for these symptoms, according to the study’s lead author, making possible approaches worth testing.

The reported changes in both participants’ assessments and some cognitive test results give researchers a reason to investigate oxaloacetate further. They do not yet show that it is an effective treatment for survivors generally. A small, short study can identify a signal, but it cannot establish how reliably the supplement works, who might benefit or whether the effects last.

Products Worth Considering

Philips Sonicare DiamondClean 9500 Electric Toothbrush, Black, with 3 Brush Heads

Philips Sonicare DiamondClean 9500 Electric Toothbrush, Black, with 3 Brush Heads

As an affiliate, we earn on qualifying purchases.

Why Researchers Tested Oxaloacetate

Symptoms often called “chemo brain” or “brain fog” are not necessarily caused by chemotherapy alone. The report notes that the cancer itself, chemotherapy, endocrine therapy, inflammation, hormonal changes and other biological or behavioral factors may contribute to cognitive difficulties after breast cancer.

The UCLA team focused on oxaloacetate because it is a molecule naturally present in the body and plays a role in cellular energy production. Researchers also considered its relationship to glutamate, which helps nerve cells communicate. They proposed that inflammation and changes in energy use or glutamate signaling could be among the processes involved in cognitive symptoms. These are scientific rationales for studying the supplement, not proof that oxaloacetate corrects those processes in patients.

The trial included 18 women, about 50 years old on average. Most had received chemotherapy, and nearly 90% were still receiving endocrine therapy during the study. The findings were published in JCO Oncology Advances, according to the supplied report.

““Cancer-related cognitive impairment can persist long after treatment ends and can have a significant impact on a person’s daily life, yet we still have very few effective treatments for it.””

— Dr. Patricia Ganz, the study’s first author and a professor at UCLA

What the Small Trial Cannot Show

The supplied report does not describe a placebo or comparison group. Without one, it is difficult to separate any effect of the supplement from other explanations, including changes over time, expectations or differences in how participants experienced and reported symptoms. The study’s 18-person enrollment also limits how confidently its results can be applied to other survivors.

The findings do not establish whether oxaloacetate benefits people with other cancers, people without substantial cognitive symptoms, or those who have completed different treatment regimens. The report also does not specify whether improvements continued after supplementation stopped. Longer and larger controlled studies are needed to test effectiveness, duration of benefit and safety across a broader group.

These results are not a recommendation for survivors to start taking the supplement. The report describes a research trial, not a clinical guideline, and the findings do not establish an appropriate use outside a study.

Larger Controlled Studies Needed

The researchers say larger studies are needed to confirm the findings. A next step would be trials with more participants and a comparison group, alongside follow-up after the treatment period. Those designs could help determine whether oxaloacetate itself accounts for the reported changes and whether benefits persist.

Until further evidence is available, the results should be treated as early research rather than established care. The supplied report does not identify a planned next trial, its timeline or whether the supplement will be tested in other survivor groups.

Key Questions

What is oxaloacetate?

Oxaloacetate is a molecule naturally present in the body that plays a role in how cells generate energy. Researchers studied it as a supplement because of its connection to cellular energy processes and glutamate regulation.

How many people took part in the study?

The phase II trial enrolled 18 women with early-stage breast cancer and substantial cognitive symptoms. Sixteen completed the full eight-week supplementation period.

Did the trial prove the supplement treats brain fog?

No. Participants who completed the study reported improvements, and some test scores improved, but the small trial was preliminary. The supplied report does not describe a comparison group, and larger studies are needed to determine whether oxaloacetate caused the changes.

What side effects were reported?

Oxaloacetate was described as generally well tolerated over eight weeks. The most frequently reported side effects were digestive complaints, including indigestion; the supplied report does not provide a complete adverse-event breakdown.

Should cancer survivors start taking oxaloacetate?

The study does not establish oxaloacetate as standard treatment or provide a clinical recommendation. Survivors considering a supplement should discuss it with a qualified health professional, particularly while receiving cancer treatment or other medication.

Source: sciencedaily.com

Wellness content on this site is informational and not a substitute for professional medical guidance.
You May Also Like

Risk Of AMD Progression After Cataract Surgery

Search and coverage interest in whether cataract surgery accelerates AMD progression is spiking. Here is what is established, claimed, and still unconfirmed.

Energizing Chair Exercises For Seniors Recommended By A Yoga Therapist

A Fit&Well report outlines a gentle seven-part chair-based movement routine for older adults, with options to adapt movements to individual comfort.

How the Pandemic Transformed Home Workouts and Fitness Tech

Fascinating shifts in home workouts and fitness technology are reshaping how we stay active—discover what’s next for your fitness journey.

FDA Approves Once-Weekly Generic Hormone Therapy Patch For Women

The FDA approved Zydus Pharmaceuticals’ generic estradiol and levonorgestrel patch, a once-weekly option for eligible women with an intact uterus.